Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma 2 Recurrence 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Leukemia 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 160 Rituximab 82 Peripheral Blood Stem Cell Transplantation 78 fludarabine phosphate 75 Etoposide 69 Filgrastim 67 Methotrexate 59 Cytarabine 58 Vincristine 50 Mycophenolic Acid 50 Whole-Body Irradiation 48 Radiotherapy 43 Cyclosporine 43 Busulfan 42 Tacrolimus 40 Melphalan 39 Dexamethasone 37 Prednisone 36 Doxorubicin 36 Antilymphocyte Serum 36 fludarabine 31 blinatumomab 27 Methylprednisolone 24 Granulocyte Colony-Stimulating Factor 22 Carmustine 22 Cord Blood Stem Cell Transplantation 21 Calcium Dobesilate 18 CT-P10 18 Inotuzumab Ozogamicin 16 sargramostim 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Burkitt Lymphoma × epratuzumab × Clear all

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡